High-risk prostate cancer: is androgen deprivation monotherapy still appropriate?
Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109-2029, USA. vahakn@umich.edu
Vahakn B
VB
Shahinian
D000726:Androgen Antagonists / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D006801:Humans; D008297:Male; D009919:Orchiectomy; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000401:mortality / Q000628:therapy*; D016032:Randomized Controlled Trials as Topic; D015996:Survival Rate
D000726:Androgen Antagonists; D000970:Antineoplastic Agents